KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Assets (2016 - 2025)

Historic Current Assets for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $593.9 million.

  • Supernus Pharmaceuticals' Current Assets fell 720.5% to $593.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $593.9 million, marking a year-over-year decrease of 720.5%. This contributed to the annual value of $686.1 million for FY2024, which is 3913.04% up from last year.
  • Supernus Pharmaceuticals' Current Assets amounted to $593.9 million in Q3 2025, which was down 720.5% from $738.9 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Current Assets high stood at $883.3 million for Q1 2023, and its period low was $423.5 million during Q2 2023.
  • Its 5-year average for Current Assets is $622.0 million, with a median of $625.1 million in 2022.
  • In the last 5 years, Supernus Pharmaceuticals' Current Assets surged by 5537.65% in 2023 and then plummeted by 3837.92% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Current Assets (Quarter) stood at $601.6 million in 2021, then grew by 22.04% to $734.2 million in 2022, then tumbled by 32.83% to $493.1 million in 2023, then surged by 39.13% to $686.1 million in 2024, then fell by 13.44% to $593.9 million in 2025.
  • Its Current Assets was $593.9 million in Q3 2025, compared to $738.9 million in Q2 2025 and $687.6 million in Q1 2025.